
|Articles|November 15, 2003
Allergan to buy Oculex for $230 million in cash
New York-Allergan Inc. will pay nearly $230 million in cash to acquire Oculex Pharmaceuticals Inc., a privately held company specializing in the development of treatments for sight-threatening diseases of the eye.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
TearSolutions advances Lacripep into phase 2 following dual FDA designations in neurotrophic keratitis
2
Oculis phase 3 DIAMOND trials miss vision endpoints in diabetic macular edema
3
Opuviz aflibercept biosimilar launches in Europe for retinal diseases
4
Study links alcohol consumption to earlier advanced presbyopia in men
5





















